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Uterine ﬁbroids (leiomyoma), the benign tumors of the uterine wall, are very common cause of morbidity in reproductive age
women usually in the form of excessive vaginal bleeding, chronic pelvic pain, miscarriage and infertility. These tumors are the
leadingindicationforhysterectomyintheUnitedStates.Uterineﬁbroidsareabout4timeshigherinblackscomparedtowhitesand
constitute a major health disparity challenge. The estimated cost of uterine ﬁbroids is up to $34.4 billion annually. Additionally,
women who suﬀer from this disease and desire to maintain their future fertility have very limited treatment choices. Currently,
there is no eﬀective long-term medicinal treatment for uterine ﬁbroids. While surgery has traditionally been the gold standard for
the treatment of uterine ﬁbroids, there is growing interest towards orally administered medications for the management of leio-
myoma-related symptoms. In this review, we will discuss these promising innovative oral medical treatments in detail.
1.Introduction
Uterine leiomyomas are the most common benign pelvic tu-
mors in women [1, 2]. They are monoclonal tumors of the
smooth muscle cells of the myometrium and consist of large
amounts of extracellular matrix that contain collagen, ﬁ-
bronectin and, proteoglycan [2, 3]. A thin pseudocapsule
that is composed of areolar tissue and compressed muscle
ﬁbers usually surrounds the tumors [4]. Leiomyomas may
enlarge to cause signiﬁcant distortion of the uterine surface
or cavity. Dark skinned women, such as African Americans,
also had higher numbers of leiomyomas and tended to have
larger uteri, which in turn may explain the higher incidence
of in-hospital complications or blood transfusion require-
m e n t si nA Aw o m e nc o m p a r e dt ow h i t ew o m e n[ 5, 6]. The
overall incidence of uterine leiomyomas is estimated to be
3-4 times higher in African American women compared
to Caucasian women [7–10]. Recent data have also con-
ﬁrmed that the age-standardized rates of ultrasound- or hys-
terectomy-conﬁrmed leiomyoma were signiﬁcantly higher in
blackwomencomparedtowhitewomen[11].Althoughthey
are benign, they commonly result in severe symptoms, such
as heavy, irregular, and prolonged menstrual bleeding as well
as anemia. Uterine leiomyomas have also been associated
with numerous other medical disorders, such as infertility,
recurrent abortion, and preterm labor [12]. These clinical
complications negatively impact women’s health. Uterine
leiomyomas are the most cited indication for the more than
600,000 hysterectomies that are performed in the US annu-
ally, and this major surgery is associated with morbidity and
mortality as well as a huge economic impact on healthcare
delivery systems that is estimated to be approximately $34.4
billion/year [13]( Table 2).
2. Current Treatment Options for
Uterine Leiomyomas
Treatment options for leiomyoma vary; treatment strategies
are typically individualized based on the severity of the
symptoms, the size and location of the leiomyoma lesions,
the patient’s age and their chronological proximity to men-
opause, and the patient’s desire for future fertility. The usual
goal of therapy is the relief of the symptoms (Table 1). The
treatment options range from the use of acupuncture (an-
cient Chinese method) to the total removal of the uterus and2 Obstetrics and Gynecology International
Table 1: The clinical presentation of uterine leiomyomas.
(i) Asymptomatic
(ii) Abnormal uterine bleeding
(a) Menorrhagia
(b) Anemia
(iii) Pelvic pressure
(a) Urinary frequency
(b) Urinary incontinence
(c) Diﬃculty with urination
(d) Hydronephrosis
(e) Constipation
(f) Tenesmus
(iv) Pelvic mass
(v) Pelvic pain
(vi) Infertility
(vii) Obstetric complications
(viii) Pregnancy related
(a) Myoma growth
(b) Red degeneration and pain
(c) Spontaneous miscarriage
(ix) Malignancy
(x) Rare associations
(a) Ascites
(b) Polycythemia
(c) Familial syndromes, renal cell carcinoma
(xi) Benign metastasizing
its myoma contents (hysterectomy) [14]. To date, there is no
deﬁnitive oral therapeutic agent for the treatment of uterine
leiomyomas, which is a reﬂection of the remarkable lack of
randomized clinical trial data that demonstrate the effective-
ness and safety of medical therapies in the management of
symptomatic leiomyomas [15].
3. Oral Medical Agents for the Treatment of
Uterine Leiomyomas
Currently, there are no deﬁnitive FDA-approved agents for
theoralmedicaltreatmentofuterineﬁbroids.However,there
are several candidate agents that can be used in addition to
otherapproachesinthemanagementofthiscommonbenign
tumor.
However, there are several candidate agents that can be
used with varying degrees of success. Increasing knowledge
of the mechanism of action of more recent candidate agents
s u c ha sV i t a m i nD ,G r e e nt e ae x t r a c t ,a n dE l a g o l i x( o r a l
GnRH antagonist) as well as that of older agents such as se-
lective estrogen receptor modulators (SERMs), antiproges-
tins, aromatase inhibitors, cabergoline, danazol, and gestri-
none may lead to the development of an oral agent with the
ability to shrink leiomyoma size with minimal side eﬀects.
This consequently will be discussed.
3.1. Vitamin D (VitD). Data from our laboratory demon-
strate that Vitamin D (VitD) is an antiﬁbrotic factor and
Table 2: Diagnosis of uterine leiomyoma.
(i) Pelvic examination: enlarged, irregular, ﬁrm, nontender uterus
(ii) Ultrasound: transvaginal ultrasound, hypoechoic, heteroge-
nous masses
(iii) Saline sonohysterography: for submucous ﬁbroids or polypi
(iv) MRI: best method for exact mapping, numbering of ﬁbroids
(v) Hysteroscopy: diagnosis of submucous ﬁbroids
inhibits growth and induces apoptosis in cultured human
leiomyoma cells through the downregulation of PCNA,
CDK1, and BCL-2 and suppresses COMT expression and
activity in human leiomyoma cells [16–18]. We have also
recently demonstrated similar eﬀects in the Eker rat model
of uterine ﬁbroids [19]. Another group in Finland demon-
strated that Vitamin D inhibits growth of both myometrial
and leiomyoma cells in vitro [20]. The growth inhibition was
concentration dependent and the level of inhibition was sta-
tistically signiﬁcant with the concentration of 1000nM.
In a separate study from our group, the correlation be-
tween low serum levels of VitD and the increased risk of hav-
ing symptomatic uterine ﬁbroids were evaluated [21, 22].
We measured both the biologically active 1, 25 dihydrox-
yvitamin D3 and the precursor 25-hydroxyvitamin D3 in
the serum from African American and white women with
ﬁbroidsaswellasnormalhealthycontrols.Interestingly,then
observed that 1, 25 dihydroxyvitamin D3 is signiﬁcantly low-
er in women with ﬁbroids compared to normal healthy con-
trols; additionally, there have been detected lower levels of
total serum 25-hydroxyvitamin D3 in women with ﬁbroids
compared to healthy controls. These ﬁndings were observed
b o t hi nA f r i c a nA m e r i c a nw o m e na n di nC a u c a s i a nw o m e n .
The aim of the study was to determine whether serum
levels of VitD correlated with disease severity in women with
symptomatic uterine ﬁbroids. The study population con-
sisted of 67 patients who had detailed repeated pelvic ultra-
sound evaluations over a 2-year period with speciﬁc mea-
surements of the total uterine volume and the volume of the
individual leiomyoma lesions. The patients also had detailed
laboratoryanalysisincludingserum25hydroxyVitD3levels.
As shown in (Figure 1), a statistically signiﬁcant negative
correlation between the low serum VitD levels and the total
uterineleiomyomavolume(P<. 05)aswellasthenumberof
leiomyoma lesions/uterus (P<. 05) was detected [23]. Taken
together, our preliminary results suggest a strong dose-res-
ponse correlation between lower serum VitD levels and in-
creased severity of uterine ﬁbroids. This presents an oppor-
tunity for the potential use of VitD or its potent analogues
as novel treatment options or for the prevention of uterine
ﬁbroids.
To date no randomized controlled trials had been im-
plemented to prospectively assess the eﬃcacy of VitD in the
management of uterine ﬁbroids.
4.EpigallocatechinGallate(EGCG):
Green Tea Extract
Teaisoneofthemostwidelyconsumedbeveragesalloverthe
world. Both the green tea and the black tea are derived fromObstetrics and Gynecology International 3
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Figure 1: Serum Vitamin D3 level (nmol/L) inversely correlates
with both mean volume and number of uterine ﬁbroids.
the leaves of the plant “Camellia sinensis”, the most signﬁ-
cant components of which are phytochemicals, of which
Green tea is thoroughly studied for its health beneﬁts.
A typical green tea beverage, prepared in a proportion of
1g leaf to 100mL water in a 3-min, brew, usually contains
250–350mg tea solids, and catechins account for 30–42% of
the dry weight of the solids [24]. It has been demonstrated
that tea constituents exhibit various biological and pharma-
cological properties such as anticarcinogenic, antioxidative,
antiallergic, antivirus, antihypertensive, antiatherosclerosis,
anticardiovascular disease and antihypercholesterolemic ac-
tivities [25, 26].
The major green tea catechins are epigallocatechin-3-
gallate (EGCG), epigallocatechin (EGC), epicatechin-3-gal-
late (ECG), and epicatechin. Catechins are a group of bi-
oﬂavonoids that exhibit antioxidant and anti-inﬂammatory
capacity. Chemically, catechins are polyhydroxylated with
water-soluble characteristics [27]. Epigallocatechin gallate
(EGCG), which is the principal catechin, comprises >40%
of the total polyphenolic mixture of green tea catechins
[28]. Grapes also contain polyphenols and catechins such
as EGCG [29]. Epigallocatechin gallate exhibits various bio-
logical activities including potent antioxidant and anti-in-
ﬂammation capacity [30].
EGCG appears to block each stage of tumorgenesis by
modulating signaling pathways involved in cell proliferation,
transformation, inﬂammation, and oxidative stress, which
areclearlyinvolvedinpathogenesisofvarioustumorsinclud-
ing uterine ﬁbroids [31]. In our laboratory, the eﬀect and
potentialmechanismsofEGCGactiononhumanleiomyoma
(HuLM) cells [32] were studied: cell proliferation and apop-
tosis were assayed; the protein levels of PCNA, CDK4, BCL2,
and BAX were examined by Western blot analysis, and it was
found that EGCG inhibits the proliferation of HuLM cells
and induces apoptosis. These results suggest that EGCG
may be a potential anti-uterine ﬁbroid agent acting through
multiple signal transduction pathways [33].
Additional validation of these ﬁndings was achieved
usingorallyadministeredEGCGtoshrinkpreexistingsubcu-
taneous leiomyoma lesions in immune-compromised mice
[32]. Previous studies have shown that EGCG inhibited the
growth of various human cancer cells, such as epidermoid
carcinoma cells [34], hepatoma cells [35], prostate carcino-
ma cells [36], and breast cancer cells [37]. Those ﬁndings
motivated us to initiate a currently ongoing double-blind
placebo-controlled clinical trial (phase II trial) to evaluate
the promising clinical role of EGCG in women with symp-
tomatic uterine ﬁbroids.
5. GnRH Antagonists
The3rd-generationGnRHantagonistsdisplayamoretolera-
b l es i d ee ﬀect proﬁle compared to the ﬁrst-generation GnRH
antagonists (histamine release and severe allergic reactions)
and the second generation GnRH antagonists (allergy and
gel formation); some of the GnRH antagonists approved for
clinical use by the US FDA include cetrorelix (Cetrotide;
Serono) and ganirelix (Antagon; Organon International).
These agents are usually used as injectables. GnRH antago-
nists exert their action through the direct competitive inhi-
bition of GnRH by occupying the pituitary GnRH receptors
and therefore blocking the access of the endogenous GnRH
and exogenously administered agonists to their receptor sites
[38, 39]. These agents may induce a deep suppression of
gonadotropins and the sex steroids, while avoiding any “ﬂare
up” phenomena, which may lead to a reduction in uterine ﬁ-
broidssizeofupto50%[40].Oneofthemajorlimitationsto
the wide use of the GnRH antagonists in leiomyoma treat-
ment is the short half-life of these agents and the non-availa-
bility of the Depot formulation, thus require repetitive dos-
ing (daily for most of the antagonists) [41].
5.1. Promising GnRH Antagonist (Elagolix). Elagolix is a sec-
ond-generation new nonpeptide (GnRH) antagonist, highly
potent antagonist orally active and rapidly bioavailable after
administration that is being developed by Abbott Laborato-
ries (Abbott) in collaboration with Neurocrine Biosciences
[42, 43]. It is ﬁnalizing the Phase III for endometriosis and
ﬁnalizing Phase II for uterine leiomyoma with opportunity
to be its ﬁrst and only approved oral treatment for uterine
leiomyoma [44]. This promising compound inhibits gona-
dotropin releasing hormone (GnRH) receptors in the pitu-
itary gland leading to a dose-dependent suppression of LH,
FSH, and estradiol. Consequently, suppression of E2 is more
prolonged at higher doses [45]. Pituitary suppression is
maintained for only a portion of the day, and baseline gona-
dotropin levels return by 24 hours [46].
These properties suggest that Elagolix may enable dose-
related pituitary and gonadal suppression in premenopausal
women as part of treatment strategies for reproductive hor-
mone-dependent disease states [46]. To date, Elagolix has
been studied in 18 clinical trials totaling more than 1,000
subjects.
Elagolix seems to be well tolerated for multipledoses
up to 200; rapidly absorbed after oral administration, with4 Obstetrics and Gynecology International
median time of maximum plasma concentration (Tmax)
values ranging from 0.5 to 1h, the primary metabolite (NBI-
61962) appears in the serum rapidly after administration
[46].
The therapeutic window of E2 levels for suppression of
endometriosis is attainable at a dose of 100–150mg/day with
serum estradiol remained between 20 and 50pg/mL [45].
This is supported by Barberi RL ﬁndings which showed that
E2 levels between 30 and 50pg/mL are eﬀective in inducing
endometrial atrophy [47]. The Elagolix therapeutic dose for
management of uterine ﬁbroid is yet to be determined.
6.SelectiveEstrogenReceptor
Modulator (SERMs)
Selective estrogen receptor modulators (SERMs) are nons-
teroidal estrogen receptor ligands that display tissue-specific
agonist-antagonist estrogenic actions. They are used fre-
quently in the treatment and prevention of estrogen recep-
tor-positive carcinoma of the breast in addition to their use
as ovulation induction agents [48, 49]. Tamoxifen is one of
the oldest known SERMs, but it may potentially cause endo-
metrial carcinoma due to its partial agonistic eﬀect on the
endometrium [50]. There are no randomized controlled
trials that have investigated the potential role of Tamoxifen
in the treatment of uterine ﬁbroids; however, a few case re-
ports have suggested that it actually increases leiomyoma
growth [48, 51]. Raloxifene is another SERM that can be
theoretically considered to be a candidate therapeutic option
for uterine ﬁbroids. Raloxifene only slightly aﬀected collagen
biosynthesis in control myometrium cells; however, it sig-
niﬁcantly inhibited collagen biosynthesis in leiomyoma cells
[52] and exerted its action at the transcriptional level [53]. A
newly developed SERM, “Lasofoxifene”, is currently awaiting
FDAapproval.However,theresultsofearlytrialssuggestthat
there were no signiﬁcant beneﬁts compared to raloxifene for
the skeleton, breast, heart, or reproductive tract [54, 55].
6.1.MechanismofAction. Themostprobablehypothesisthat
explains SERMs’ mechanism of action is that they induce
changes in estrogen receptors, which result in diﬀerential
expression of speciﬁc estrogen-regulated genes in diﬀerent
tissues [56]. Every member of the SERM family has its own
individual characteristics, which depend on its structure, the
type of estrogen receptor they bind to, and the set of mole-
cules that interact with its estrogen receptor/SERM complex
in aﬀected cells, and these characteristics result in either ago-
nistic or antagonistic activity [57]. SERMs could potentially
provide therapeutic beneﬁts by having antagonistic eﬀects at
uterine myometrial level and by preventing ovarian stimula-
tion which has been achieved in rat studies. The diﬀerence in
activity of SERMs is based on the structure activity relation-
ships (SARs) [58].
6.2. SERMs and Treatment of Uterine Fibroids. All SERMs,
with their estrogen blocking activity, would be theoretically
expected to exert at least some therapeutic eﬀect on uterine
ﬁbroids.Raloxifenehasbeenshowntoenhancetheshrinkage
of uterine ﬁbroids in postmenopausal women [59, 60].
However, a recent report from Italy that addressed the eﬀect
of raloxifene on uterine leiomyoma showed that the leiomy-
oma size in premenopausal women who were administered
daily 60mg doses of raloxifene over a 2-year period exhibited
no change in leiomyoma size [61].
6.3. Adverse Events. Tamoxifen is not recommended for
women with a prior history of deep venous thrombosis,
pulmonary embolus, stroke, or transient ischemic attack be-
cause it increases the risk of ischemic stroke, particularly in
women who are 50 years of age or older. Additionally, the
risk of uterine/endometrial cancer was approximately dou-
bled with tamoxifen use [62], and the risk of superﬁcial
thrombophlebitis was three times higher [41, 50]. Some of
these side eﬀects could be explained by the inhibition of cel-
lular glutamine uptake, oxidative stress, and the induction of
apoptosis [63]. SERMs are seldom used for the treatment of
uterine ﬁbroids [52].
7. AromataseInhibitors
Aromatase inhibitors (AIs) signiﬁcantly block both ovarian
and peripheral estrogen production within 1 day of treat-
ment [64]. Letrozole suppressed the production of estrogens,
particularly estrone and estradiol, by 76–79% compared to
their baseline levels [65]. The underlying mechanism is the
inhibitionofthearomataseenzyme,whichistheenzymethat
catalyzes the conversion of androgenic substances into estro-
gens [66]. Recent reports have suggested that aromatase is
expressed to a greater extent in uterine leiomyoma tissues of
African-American women compared to Caucasian women,
which may contribute to the higher incidence of ULMs in
African American women [67]. Aromatase inhibitors have
been shown to be eﬀective against ﬁbroids in limited short
term studies with dosing regimens that included 2.5mg per
day of letrozole and 1mg per day of anastrozole [68]. One of
themajorconcernswiththeuseofaromataseinhibitorsisthe
reportedbonelosswithprolongeduse,whichnecessitatesthe
concomitant use of oral contraceptive pills or progesterone
[69]. A recently published RCT compared the eﬀects of three
months of aromatase inhibitor (letrozole) to that of three
months of gonadotropin-releasing hormone agonist (trip-
torelin) on uterine leiomyoma volume and hormonal status
[70]. The results showed an advantage of the rapid onset of
action of AIs in addition to the avoidance of the ﬂare ups
that initially occurs with GnRHa. Both treatment options in-
duced signiﬁcant shrinkage of the uterine ﬁbroids and im-
provement in leiomyoma-associated symptoms [70]. The
mean reduction of leiomyoma volume with 3-month use of
anastrozoleis55.7%[71].Theauthorssuggestedthataroma-
tase inhibitors should be considered in women with ﬁbroids
on a short-term basis or in women who want to avoid sur-
gical intervention to preserve their potential fertility [72].
Another concern with the use of AIs as a treatment option
for uterine leiomyoma is its oﬀ-label use, which man-
dates a thorough review with patients prior to the initiation
of the therapy [69]. Several RCTs are underway that wouldObstetrics and Gynecology International 5
hopefully add to our understanding of the potential promis-
ing role of AIs in the treatment of uterine leiomyomas [62].
8.Antiprogesterones
Estrogen has traditionally been considered to be the most
important stimulus for leiomyoma growth and numerous
studies that included cell culture and animal models sup-
portedthisconcept[73].Surprisingly,recentﬁndingssuggest
that volume maintenance and growth of human ULMs are
also heavily progesterone dependent, and hence antiproges-
terone could reverse leiomyoma growth eﬀects [74, 75]. One
potential link between the eﬀects of the two key steroid hor-
mones on ULMs is that estradiol induced the expression of
theprogesteronereceptorandsupportedprogesteroneaction
on leiomyoma tissue [73]. Clinical ﬁndings also support
these laboratory observations; studies have involved the eval-
uation of mifepristone (RU 486) [76–78], azoprisnil [68, 75],
and, more recently, CDB-2914 and CDB-4124 (CDB: Con-
traceptive Development Branch) [79].
8.1. Mifepristone. Mifepristone (RU486), a well-known oral
antiprogesterone compound, has been used for more than
20 years for multiple clinical indications [70, 80–82]. It has
recently been evaluated as a potential therapeutic agent for
uterine ﬁbroids with a dose that ranges from 5mg to 50mg
overa3-monthperiod[83–85].Mifepristonereducedleiom-
yoma size (26% to 74%) and improved leiomyoma related
symptoms (63% to 100% induction of amenorrhea). Re-
ported side eﬀects included transient elevations in transam-
inases, which occurred in 4% of cases as well as endometrial
hyperplasiaandwasdetectedin28%ofthewomenwhowere
screened with endometrial biopsies [86]. However, these
studies were mostly preliminary with limited numbers of
subjects, and therefore, larger randomized well-controlled
trials that include thorough monitoring of liver function and
endometrial histology are required to conclusively determine
the safety and eﬃcacy of this treatment modality.
8.2. Asoprisnil. Asoprisnil (J867, BAY86-5294) is an investi-
gational selective progesterone receptor modulator (SPRM)
that was developed for the treatment of progesterone-sensi-
tive myomata. It induces unique morphological changes and
isassociatedwithinhibitedproliferationoftheendometrium
and leiomyomata. These changes may lead to amenorrhea,
which is usually encountered with its use [68, 87, 88]. Aso-
prisnil is a tissue selective molecule that binds to the proges-
terone receptors with a threefold greater aﬃnity than endo-
genous progesterone [83]. It reduces the uterine and leiomy-
oma volumes in a dose-dependent manner while achieving
remarkable decreases in menorrhagia scores in women with
menorrhagia [89]. Amenorrhea rates also increased as the
dose of asoprisnil was increased [84, 87]. When asoprisnil
was administered daily for longer than 3-4 months, signiﬁ-
cant endometrial thickening and unusual histological ap-
pearance of the endometrial glands occurred [85].
8.3. Telapristone Acetate/CDB-4124 (Proposed Trade Names,
Proellex, Progenta). CDB-4124 is another SPRM, but it is
a relatively pure progesterone antagonist. It was studied in
recent years for the treatment of uterine ﬁbroids and is still
being evaluated to address its safety and dose parameters in
premenopausal women [90]. Limited information or publi-
cations are currently available on the various clinical trials
that have investigated CDB-4124; these studies have either
been completed or were terminated due to adverse liver-
related events according to the http://www.clinicaltrials.gov/
website. New clinical trials using lower doses of CDB-4124
have recently been approved by the FDA.
8.4. Ulipristal/CDB-2914 (VA 2914, EllaOne, Ella). Ulipristal
is an FDA-approved selective progesterone receptor modu-
lator (SPRM) that is indicated for emergency contraception.
It is structurally similar to mifepristone and seems to be ef-
fective in the treatment of uterine ﬁbroids. It is associated
with a reduction in pain, bleeding, and leiomyoma size be-
tween 17 and 24% [91], as well as an improvement in quality
of life [92]. However, data on long-term treatment are lack-
ing, and similar to other SPRMs, ulipristal may be associated
with endometrial thickening and endometrial hyperplasia
[85, 93, 94]. Large randomized well-controlled clinical trials
are needed to evaluate the utility of ulipristal for potential
clinical treatment of uterine ﬁbroids [93].
9.Somatostatin Analogues
Increasing evidence has demonstrated a role for growth fac-
tors, such as insulin growth factor I (IGF-I) and IGF-II, in
the initiation and progression of uterine ﬁbroids [95–98].
Leiomyoma tissue expresses higher levels of IGF-I/IGF-II
receptors compared to normal adjacent myometrium [89,
97]. Additionally, these tissues secrete their own IGF-1,
probably for autocrine and paracrine use [98]. From a clin-
ical perspective, it has been recently reported that patients
with high levels of growth hormone (acromegalic patients)
have a higher prevalence of uterine ﬁbroids than the gen-
eral population [99]. Lanreotide, which is a long-acting so-
matostatin analogue that has been shown to reduce growth
hormone secretion, has also recently been evaluated in seven
women with uterine ﬁbroids in Italy [100]. Interestingly,
lanreotide induced a 42% mean myoma volume reduction
within a 3-month period. These results show that somato-
statin analogues may potentially be a new therapy for uterine
ﬁbroids [101]. The treatment with somatostatin analogues
for diseases other than leiomyoma appears to be safe and
is usually well tolerated with some reports of gallstone for-
mation [102, 103]. However, the lacking of clinical trials
whichtestthelong-termuseofsomatostatinanaloguesalong
with the severe and adverse health implications such as
decreased life expectancy due to accelerated heart disease ob-
servedin adultswith growth hormone deﬁciencymay hinder
its future use for leiomyoma treatment.
10.Cabergoline
Carbergoline is a well-known dopamine agonist that is ef-
fectively used in the treatment of prolactinoma and for6 Obstetrics and Gynecology International
the inhibition of lactation. A recent study [104]e v a l u a t e d
carbergoline as a therapeutic option for uterine ﬁbroids.
The rational for such an approach lies in its eﬀect as an
inhibitory agent on GnRH release. A group in Iran published
a preliminary study in 2007 [104] that favored the use of
carbergoline as a medical treatment of uterine ﬁbroids on
which they reported a volume reduction of about 50% with
6-week use [92] .T h es a m eg r o u pp e r f o r m e das u b s e q u e n t
study that compared carbergoline with diphereline, which
is a gonadotropin-releasing hormone agonist [105]. They
reported comparable results in terms of the shrinkage of the
ﬁbroids and the improvement in the sonographic, clinical,
and intraoperative outcomes [105]. These ﬁndings warrant
future larger controlled trials to clearly assess the potential
use of carbergoline in the treatment of uterine ﬁbroids.
11.Danazol
Danazol is a synthetic steroid that inhibits steroidogenesis
through multienzymatic actions in addition to its suppressor
eﬀect on sex hormone binding globulin [106]. It reportedly
induced a signiﬁcant 24% volume reduction [107, 108].
However, a recent Cochrane study failed to identify any ran-
domized controlled trials that compared danazol to placebo
or any other medical therapy in women with uterine ﬁbroids
[109].
12. Gestrinone
Gestrinone is a steroid that possesses antiestrogen receptor
and antiprogesterone receptor properties in various tissues,
including the endometrium [110] .Ar e c e n tr e p o rtf r o mI t a l y
evaluated the use of Gestrinone in the treatment of pre-
menopausal women with uterine ﬁbroids at a dose of 2.5mg
twice per week over a 6-month period [110]. The authors re-
ported a 32% ± 10% reduction in uterine volume [110]. A
subsequent study reported up to 60% leiomyoma shrinkage
in size [111]. Gestrinone is a contraceptive agent and also ex-
hibits several unfavorable side eﬀects, such as mild andro-
genicity, weight gain, seborrhea, acne, hirsutism, and occa-
sional hoarseness.
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